Efficacy and Safety of Ferric Carboxymaltose Injection in Pregnant women:Retrospective analysis at Indian Real-life Scenario

Gupte Hospital0 个研究点目标入组 168 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Pregnant female patients aged more than 18 years of age who visited to department of Obstetrics and Gynecology in their 2nd and 3rd trimester of gestation.
•2. Documented Iron deficiency anemia and received FCM injection.
•3. Data for hematological parameters (hemoglobin, serum ferritin) are available at baseline and for minimum at 4 Â± 2 weeks.
•4. Patients already provided informed consent for future use of their medical records for research.

•1. Any other type of anemia apart from Iron Deficiency anemia
•2. Evidence of iron overload conditions (e.g. hemochromatosis / hemosiderosis).
•3. Any malignancy.
•4. Presence of active liver disease/ HBV or HCV infection, CKD, HIV infection / AIDS, asthma, or rheumatoid arthritis.
•5. Any condition that, in the opinion of the investigator, does not justify the patientâ??s inclusion in the study.

发起方

Gupte Hospital